Logo

AnVil, Genomics Collaborative to Build New CV Products

Nov 05, 2002

NEW YORK, Nov. 5-AnVil and Genomics Collaborative will work together to develop new products and resources for the life sciences market, AnVil said today.

 

Using its informatics and data visualization capabilities, AnVil will analyze cardiovascular clinical data from GCI's database. The two companies will build predictive and analytic models for coronary artery disease, myocardial infarction, hyperlipidemia and hypertension.

 

From this collaboration, the companies hope to develop products that will be useful to pharmaceutical and biotech companies in cardiovascular drug development. They will jointly develop a marketing and business plan.

 

AnVil is a data management and visualization company based in Burlington, Mass.

 

The two companies struck a deal to develop drugs for rheumatoid arthritis in April 2002.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.